Thinking of joining a study?

Register your interest

NCT04324164 | RECRUITING | Non-small Cell Lung Cancer


Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced NSCLC
Sponsor:

Hunan Province Tumor Hospital

Information provided by (Responsible Party):

Long Zhang

Brief Summary:

This study aims to explore Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced Non-small Cell Lung Cancer in China

Condition or disease

Non-small Cell Lung Cancer

Intervention/treatment

Third-generation EGFR-TKI

EGFR-TKI

Detailed Description:

inclusion criteria Uncommon EGFR Mutant Advanced Non-small Cell Lung Cancer EGFR G719X, exon 20 insert mutation without any anti-cancer treatment history

Study Type : OBSERVATIONAL
Estimated Enrollment : 800 participants
Official Title : Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced Non-small Cell Lung Cancer in China
Actual Study Start Date : 2020-03-24
Estimated Primary Completion Date : 2025-12-24
Estimated Study Completion Date : 2027-12-24

Information not available for Arms and Intervention/treatment

Ages Eligible for Study: 18 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers:
Criteria
Inclusion Criteria
  • * 18,Advanced Non-squamous Non-small Cell Lung Cancer Confirmed by Histopathology
  • * Uncommon EGFR Mutant Advanced NSCLC
Exclusion Criteria
  • * Patients with contraindication of chemotherapy
  • * Pregnant or breast feeding women

Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced NSCLC

Location Details

NCT04324164


Please Choose a site



How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations


RECRUITING

China, Hunan

Long Zhang

Changsha, Hunan, China, 410013

Loading...